

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A peptide comprising an amino acid sequence of GLP-1(7-35) having deletion, substitution and/or addition of one or a few amino acids and having a GLP-1 activity with Waa-(Xaa)<sub>n</sub>-Yaa (in which Waa is Arg or Lys, Xaa is ~~Arg or Lys~~ the same with Waa, n is an integer of 0 to 14, and Yaa is Arg, ~~Arg-NH<sub>2</sub>~~, ~~Lys, Lys-NH<sub>2</sub> or Hse~~) or Arg-NH<sub>2</sub> on its C-terminus of the peptide.

2. (original) A peptide according to claim 1, wherein the amino acid sequence of GLP-1 is substituted at position 8 with Ser.

3. (original) A peptide according to claim 1, wherein the amino acid sequence of GLP-1 is substituted at position 26 with Gln and at position 34 with Asn.

4. (original) A peptide according to claim 1, wherein n is an integer of 1 to 9.

5. (original) A peptide according to claim 1, wherein n is an integer of 3 to 5.

6. (currently amended) A peptide according to claim 1, which is represented by the general formula:  $[\text{Ser}^8, \text{Gln}^{26}, \text{Asn}^{34}]$  wherein the amino acid sequence of GLP-1(7-35) (Arg)<sub>n</sub> Yaa (in which n is an integer of 4 to 6, and Yaa is Arg or Arg-NH<sub>2</sub>) is substituted at position 8 with Ser, at position 26 with Gln and at position 34 with Asn.

7. (currently amended) A peptide according to ~~any one of claims 1 to 3~~ claim 1, which has a higher efficiency of transmucosal absorption than that of naturally occurring GLP-1.

8. (currently amended) A pharmaceutical composition for transmucosal administration containing as an active ingredient a peptide ~~according to any one of claims 1 to 3~~ comprising an amino acid sequence of GLP-1(7-35) having deletion, substitution and/or addition of one or a few amino acids and having a GLP-1 activity with Waa-(Xaa)<sub>n</sub>-Yaa (in which Waa is Arg or Lys, Xaa is Arg or Lys, n is an integer of 0 to 14, and Yaa is Arg, Arg-NH<sub>2</sub>, Lys, or Lys-NH<sub>2</sub>) on its C-terminus of the peptide.

9. (original) A pharmaceutical composition according to claim 8, which contains a fat emulsion regulated to be negatively charged thereon.

10. (currently amended) A pharmaceutical composition according to claim 8 or 9, which is used for transmucosal administration, particularly for nasal administration.

11. (currently amended) A pharmaceutical composition according to claim 8 or 9, which is used in treatment of non-insulin dependent chronic diabetes mellitus, treatment of insulin dependent chronic diabetes mellitus, treatment of obesity and/or suppression of appetite.

12. (new) A peptide according to claim 1, comprising an amino acid sequence of GLP-1(7-35), including the one in which position 8 is substituted with Ser, the one in which position 26 is substituted with Gln, and the one in which position 34 is substituted with Asn, having Waa-(Xaa)<sub>n</sub>-Yaa (in which Waa is Arg or Lys, Xaa is the same with Waa, n is an integer of 0 to 14, and Yaa is Arg or Arg-NH<sub>2</sub>) added to the C-terminus of the peptide.

13. (new) A pharmaceutical composition according to claim 8, wherein the peptide contained as an active ingredient comprises an amino acid sequence of GLP-1(7-35) having deletion, substitution and/or addition of one or a few amino acids and having a GLP-1 activity with Waa-(Xaa)<sub>n</sub>-Yaa (in which Waa is Arg or Lys, Xaa is the same with Waa, n is an integer of 0 to 14, and Yaa is Arg or Arg-NH<sub>2</sub>) on its C-terminus of the peptide.

14. (new) A pharmaceutical composition according to claim 8, wherein the peptide contained as an active ingredient comprises an amino acid sequence of GLP-1(7-35), including the one in which position 8 is substituted with Ser, the one in which position 26 is substituted with Gln, and the one in which position 34 is substituted with Asn, having Waa-(Xaa)<sub>n</sub>-Yaa (in which Waa is Arg or Lys, Xaa is the same with Waa, n is an integer of 0 to 14, and Yaa is Arg or Arg-NH<sub>2</sub>) added to the C-terminus of the peptide.

15. (new) A pharmaceutical composition according to claim 8, wherein the peptide contained as an active ingredient comprises an amino acid sequence of [Ser<sup>8</sup>]-GLP-1(7-35) with Waa-(Xaa)<sub>n</sub>-Yaa (in which Waa is Arg or Lys, Xaa is the same with Waa, n is an integer of 0 to 14, and Yaa is Arg or Arg-NH<sub>2</sub>) on its C-terminus of the peptide.

16. (new) A method for treating non-insulin dependent diabetes mellitus, insulin dependent diabetes mellitus and/or obesity which comprises transmucosally administering to the patient the pharmaceutical composition containing as an active ingredient a peptide comprising an amino acid sequence of GLP-1(7-35) having deletion, substitution and/or addition of one or a few amino acids and having a GLP-1 activity with Waa-(Xaa)<sub>n</sub>-Yaa (in which Waa is Arg or Lys, Xaa is Arg or Lys, n is

an integer of 0 to 14, and Yaa is Arg, Arg-NH<sub>2</sub>, Lys, or Lys-NH<sub>2</sub>) on its C-terminus of the peptide.

17. (new) A method according to claim 16, wherein the pharmaceutical composition contains as an active ingredient a peptide comprising an amino acid sequence of [Ser<sup>8</sup>]-GLP-1(7-35) with Waa-(Xaa)<sub>n</sub>-Yaa (in which Waa is Arg or Lys, Xaa is the same with Waa, n is an integer of 0 to 14, and Yaa is Arg or Arg-NH<sub>2</sub>) on its C-terminus of the peptide.